| Cellectar Biosciences Inc. (CLRB) Q1 2025 Earnings Call Transcript |
Cellectar Biosciences Inc. (NASDAQ:CLRB ) Q1 2025 Earnings Conference Call May 13, 2025 8:30 AM ET Company Participants Jim Caruso - President and CEO Chad Kolean - CFO Jarrod Longcor - COO Anne Marie Fields - IR, Managing Director, Precision AQ Conference Call Participants Aydin Huseynov - Ladenburg Thalmann Operator Ladies and gentlemen, thank you for standing by, and welcome. At this time all participants are in listen-only mode. |
seekingalpha.com |
2025-05-13 18:17:16 |
Czytaj oryginał (ang.) |
| Cellectar Biosciences Reports First Quarter 2025 Financial Results and Provides a Corporate Update |
Company Seeking Conditional Approval from European Medicines Agency (EMA) for Iopofosine I 131 in Waldenstrom Macroglobulinemia based upon CLOVER WaM Phase 2 Study Data |
globenewswire.com |
2025-05-13 11:05:00 |
Czytaj oryginał (ang.) |
| Cellectar Biosciences to Report First Quarter Financial Results and Host a Conference Call on Tuesday, May 13, 2025 |
FLORHAM PARK, N.J., May 07, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that the Company will report financial results for the first quarter ended March 31, 2025, and provide a corporate update on May 13, 2025, at 8:30 a.m. Eastern Time. |
globenewswire.com |
2025-05-07 12:05:00 |
Czytaj oryginał (ang.) |
| Cellectar Announces Plan to Explore Strategic Alternatives |
FLORHAM PARK, N.J., April 30, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that the company will explore a full range of strategic alternatives to advance its promising platform and radiopharmaceutical drug development pipeline to maximize stockholder value. Strategic alternatives under consideration may include, but are not limited to mergers, acquisitions, partnerships, joint ventures, licensing arrangements or other strategic transactions. The company's board of directors has approved the engagement of Oppenheimer & Co. Inc. to serve as exclusive financial advisor to assist in the strategic evaluation process. |
globenewswire.com |
2025-04-30 12:05:00 |
Czytaj oryginał (ang.) |
| 4 Medical Product Stocks to Buy From a Challenging Industry |
The U.S. government's tariff imposition, especially on China, is likely to keep supply chains under pressure for the Zacks Medical Products industry. PODD, MGNX, CLRB and ALUR are likely to gain from the favorable factors. |
zacks.com |
2025-04-17 13:55:37 |
Czytaj oryginał (ang.) |
| Is Cellectar Biosciences (CLRB) Stock Outpacing Its Medical Peers This Year? |
Here is how Cellectar Biosciences, Inc. (CLRB) and Cencora (COR) have performed compared to their sector so far this year. |
zacks.com |
2025-03-18 12:47:00 |
Czytaj oryginał (ang.) |
| Cellectar Biosciences Inc. (CLRB) Q4 2024 Earnings Call Transcript |
Cellectar Biosciences Inc. (NASDAQ:CLRB ) Q4 2024 Earnings Conference Call March 13, 2025 8:30 AM ET Company Participants Anne Marie Fields – Managing Director-Precision AQ Jim Caruso – President and Chief Executive Officer Chad Kolean – Chief Financial Officer Jarrod Longcor – Chief Operating Officer Conference Call Participants Jonathan Aschoff – ROTH Operator Ladies and gentlemen, thank you for standing by, and welcome. At this time all participants are in listen-only mode. |
seekingalpha.com |
2025-03-13 14:41:14 |
Czytaj oryginał (ang.) |
| Cellectar Biosciences Reports Financial Results for Year Ended 2024 and Provides a Corporate Update |
Achieves alignment with U.S. Food and Drug Administration (FDA) on regulatory path for potential accelerated approval of iopofosine I 131 as a treatment for Waldenström macroglobulinemia (WM) |
globenewswire.com |
2025-03-13 09:05:00 |
Czytaj oryginał (ang.) |
| Cellectar Biosciences to Report Full Year Financial Results and Host a Conference Call on Thursday, March 13, 2025 |
FLORHAM PARK, N.J., March 05, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that the company will report financial results for the full year ended December 31, 2024, and provide a corporate update on March 13, 2025, at 8:30 a.m. Eastern Time. |
globenewswire.com |
2025-03-05 10:05:00 |
Czytaj oryginał (ang.) |
| Cellectar Biosciences to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference |
FLORHAM PARK, N.J., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that members of its management team will present an overview of the company at the upcoming Oppenheimer 35th Annual Healthcare Life Sciences Conference being held virtually. Details are as follows: |
globenewswire.com |
2025-02-05 10:05:00 |
Czytaj oryginał (ang.) |
| Cellectar Biosciences to Highlight 2025 Strategic Initiatives at Upcoming Biotech Showcase during the JP Morgan Healthcare Conference |
Oral Presentation Presented at ASH 2024 Showed Iopofosine I 131 Achieved an 83.6% ORR and Exceeded Primary and Secondary Efficacy Endpoints in Phase 2 CLOVER-WaM Study for Relapsed/Refractory Waldenstrom's Macroglobulinemia |
globenewswire.com |
2025-01-12 20:00:00 |
Czytaj oryginał (ang.) |
| Wall Street's top 5 stocks with the biggest upside in 2025 |
As 2024 is nearing its end, investors with a time machine are looking to visit December 2023 and take their long positions in Nvidia (NASDAQ: NVDA), Tesla (NASDAQ: TSLA), Super Micro Computer (NASDAQ: SMCI) – though with a sell order placed for April – and myriad Chinese stocks, again, with a sell order for October 1. |
finbold.com |
2024-12-26 08:15:00 |
Czytaj oryginał (ang.) |
| Cellectar Biosciences Stock Plunges As Cancer-Focused Cancer Firm Pursues Strategic Options |
On Tuesday, Cellectar Biosciences, Inc. CLRB unveiled a strategic update on its clinical development programs for its proprietary phospholipid ether drug conjugate platform, which targets cancer. |
benzinga.com |
2024-12-11 13:25:02 |
Czytaj oryginał (ang.) |
| Cellectar Biosciences Provides Strategic Update on Clinical Development, Pipeline Programs and Corporate Restructuring |
Evaluating strategic options for iopofosine I 131 a late-stage clinical program with compelling Phase 2 data and a substantial market opportunity |
globenewswire.com |
2024-12-10 19:00:00 |
Czytaj oryginał (ang.) |
| Cellectar Biosciences, Inc. (CLRB) Q3 2024 Earnings Call Transcript |
Cellectar Biosciences, Inc. (NASDAQ:CLRB ) Q3 2024 Earnings Conference Call November 18, 2024 8:30 AM ET Company Participants Anne Marie Fields - Managing Director, Precision AQ Jim Caruso - President & CEO Chad Kolean - CFO Andrei Shustov - SVP, Medical Shane Lea - Chief Commercial Officer Jarrod Longcor - COO Conference Call Participants Jeff Jones - Oppenheimer Operator Ladies and gentlemen, thank you for standing by. And welcome at this time, all participants are in listen only mode. |
seekingalpha.com |
2024-11-18 12:59:30 |
Czytaj oryginał (ang.) |
| Cellectar Biosciences Reports Financial Results for Q3 2024 and Provides a Corporate Update |
Phase 2 CLOVER-WaM pivotal study data selected for oral presentation at 66 th Annual American Society of Hematology Meeting and Exposition |
globenewswire.com |
2024-11-18 09:05:00 |
Czytaj oryginał (ang.) |
| Cellectar Biosciences and NorthStar Medical Radioisotopes Announce Partnership for Supply of Actinium-225 |
NorthStar to provide Cellectar with non-carrier-added Ac-225 for its expanded portfolio of clinical programs |
globenewswire.com |
2024-11-14 10:05:00 |
Czytaj oryginał (ang.) |
| Cellectar Biosciences and SpectronRx Partner to Manufacture Novel Phospholipid Radioconjugate for the Treatment of Cancer |
Cellectar broadens global manufacturing network in preparation for potential commercialization of Iopofosine I 131 in 2025 Cellectar broadens global manufacturing network in preparation for potential commercialization of Iopofosine I 131 in 2025 |
globenewswire.com |
2024-11-12 10:05:00 |
Czytaj oryginał (ang.) |
| Cellectar Biosciences to Report Third Quarter Financial Results and Host a Conference Call on Monday, November 18, 2024 |
FLORHAM PARK, N.J., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that the company will report financial results for the three months ended September 30, 2024, and provide a corporate update on November 18, 2024, at 8:30 a.m. Eastern Time. |
globenewswire.com |
2024-11-11 18:05:00 |
Czytaj oryginał (ang.) |
| Cellectar Selected to Present New Data from Phase 2 CLOVER-WaM Study in Oral Session at ASH 2024 |
Ailawadhi, Sikander, M.D., Lead Investigator, to Present Iopofosine I 131 Efficacy and Safety Results from Phase 2 CLOVER-WaM Study |
globenewswire.com |
2024-11-07 08:40:00 |
Czytaj oryginał (ang.) |
| Cellectar Biosciences Announces Compliance Regarding Filing of Form 10-Q |
FLORHAM PARK, N.J., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company, announced today it received a letter dated October 31, 2024, from Nasdaq, Inc. informing the Company that it had regained compliance with Nasdaq Listing Rule 5250(c)(1). The Company filed the following on October 29, 2024, with the Securities and Exchange Commission: (i) restated audited consolidated financial statements for the fiscal years ended December 31, 2023 and 2022 and restated quarterly financial statements for the periods ended March 31, 2023; June 30, 2023; September 30, 2023; March 31, 2022, June 30, 2022, and September 30, 2022 on Form 10-K/A; (ii) restated quarterly consolidated financial statements for the three months ended March 31, 2024 on Form 10-Q/A; and (iii) quarterly financial statements for the three and six months ended June 30, 2024 on Form 10-Q. The letter from Nasdaq noted that the matter is now closed. |
globenewswire.com |
2024-11-01 19:00:00 |
Czytaj oryginał (ang.) |
| Cellectar Biosciences to Present at IWWM Featuring Iopofosine I 131 |
CLRB announces two presentations featuring its Iopofosine I 131 at the 12th IWWM, in Prague. Jorge Castillo will be the presenter. |
zacks.com |
2024-08-30 18:42:04 |
Czytaj oryginał (ang.) |
| Iopofosine I 131 Featured in Two Separate Presentations at 12th International Workshop on Waldenstrom's Macroglobulinemia |
Jorge Castillo, M.D. to Present Iopofosine I 131 Activity in Bing-Neel Syndrome Andrei Shustov, M.D. |
globenewswire.com |
2024-08-26 10:40:00 |
Czytaj oryginał (ang.) |
| Cellectar to Restate Previously Issued Financial Statements – Company Announces Receipt of Expected Delinquency Notification Letter from Nasdaq |
FLORHAM PARK, N.J., Aug. 23, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced that the Company had received an expected delinquency notification letter (the “Notice”) from the Listing Qualifications Staff of the Nasdaq Stock Market LLC (“Nasdaq”) on August 20, 2024. The Notice indicated that the Company is not in compliance with the periodic financial report filing requirement set forth in Nasdaq Listing Rule 5250(c)(1) as a result of the Company's delay in filing its Quarterly Report on Form 10-Q for the quarter ended June 30, 2024 (the “Second Quarter 10-Q”), by the applicable due date. |
globenewswire.com |
2024-08-23 21:00:00 |
Czytaj oryginał (ang.) |
| Cellectar Biosciences, Inc. (CLRB) Q2 2024 Earnings Call Transcript |
Cellectar Biosciences, Inc. (NASDAQ:CLRB ) Q2 2024 Earnings Conference Call August 13, 2024 8:30 AM ET Company Participants Jim Caruso – President and Chief Executive Officer Andrei Shustov – Senior Vice President-Medical Jarrod Longcor – Chief Operating Officer Shane Lea – Chief Commercial Officer Chad Kolean – Chief Financial Officer Conference Call Participants Jonathan Aschoff – ROTH Jeff Jones – Oppenheimer Ted Tenthoff – Piper Sandler Operator Good morning, and welcome to Cellectar Biosciences Second Quarter 2024 Financial Results Call. Today's call is being recorded. |
seekingalpha.com |
2024-08-13 17:25:06 |
Czytaj oryginał (ang.) |
| Cellectar Biosciences Reports Financial Results for Q2 2024 and Provides a Corporate Update |
FLORHAM PARK, N.J., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced financial results for the quarter ended June 30, 2024, and provided a corporate update. |
globenewswire.com |
2024-08-13 10:40:00 |
Czytaj oryginał (ang.) |
| UPDATE -- Cellectar Biosciences to Announce Second Quarter Financial Results and Host a Conference Call on Tuesday, August 13, 2024 |
FLORHAM PARK, N.J., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced that the company will provide a corporate update for the three months ended June 30, 2024, on Tuesday, August 13, 2024. Management will also host a conference call with investors to discuss financial results and provide an overview at 8:30 am Eastern Time. Details for the call are as follows: |
globenewswire.com |
2024-08-08 21:15:00 |
Czytaj oryginał (ang.) |
| Cellectar: WM Treatment Data Leads To A Few Regulatory Milestones |
Cellectar Biosciences, Inc. announced that the primary endpoint was met in the pivotal phase 2 CLOVER WaM study, using iopofosine for the treatment of patients with relapsed/refractory Waldenstrom's Macroglobulinemia or WM. The NDA submission of ipofosine for relapsed/refractory WM patients is expected in Q4 of 2024. The potential to have therapy given Priority Review. The company believes that the possible market for relapsed/refractory WM patients in the United States stands at a $1.05 billion market opportunity. |
seekingalpha.com |
2024-07-23 19:09:01 |
Czytaj oryginał (ang.) |
| Cellectar Biosciences' Iopofosine I 131 Exceeds Primary Endpoint in Waldenstrom's Macroglobulinemia Pivotal Study with 78% of Major Response Patients Remaining Progression Free at 18 Months |
56.4% major response rate exceeded 20% primary endpoint 98.2% disease control rate achieved in heavily pretreated patients Responses shown in difficult-to-treat, high-needs patient populations with approximately 27% of patients refractory to all available therapies and 40% dual-class refractory (BTKi and rituximab) FLORHAM PARK, N.J., July 23, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced positive results from its CLOVER WaM pivotal study evaluating iopofosine I 131, a potential first-in-class, targeted radiotherapeutic candidate for the treatment of relapsed/refractory Waldenstrom's macroglobulinemia (WM) patients that received at least two prior lines of therapy, including Bruton tyrosine kinase inhibitors (BTKi's). |
globenewswire.com |
2024-07-23 10:40:00 |
Czytaj oryginał (ang.) |
| Cellectar Biosciences Announces Exercise of Tranche B Warrants and Purchase of New Warrants for Approximately $19.4 million with the Potential to Raise Up to an Additional $73.3 Million |
FLORHAM PARK, N.J., July 22, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that the majority of Tranche B warrants issued under its September 2023 private placement have been exercised for Series E preferred stock, convertible into the company's common stock, by the participants of the previous financing, led by Rosalind Advisors, in exchange for a reduced, as-converted common stock price of $2.52 and the purchase of new warrants. The exercised Tranche B warrants and newly purchased warrants will generate gross proceeds of approximately $19.4 million. The new warrants purchased by investors have the potential to generate up to an additional $73.3 million in gross proceeds, if exercised. |
globenewswire.com |
2024-07-22 10:40:00 |
Czytaj oryginał (ang.) |
| Cellectar Biosciences to Host Key Opinion Leader Event to Review the Full Results from Its CLOVER WaM Pivotal Trial and Waldenstrom's Macroglobulinemia Market Landscape |
FLORHAM PARK, N.J., June 27, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced it will host an event on July 24, 2024, at 8:00 a.m. |
globenewswire.com |
2024-06-27 10:40:00 |
Czytaj oryginał (ang.) |